Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Encenicline in Mild to Moderate Alzheimer's Disease
NCT02327182Phase 3Terminated
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Dec 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of encenicline in Alzheimer's disease (AD), sponsored by Mitsubishi Tanabe Pharma Corporation. Started Dec 2014; status: terminated.
02
Drugs
encenicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02327182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02327182.